<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04774094</url>
  </required_header>
  <id_info>
    <org_study_id>C3591026</org_study_id>
    <nct_id>NCT04774094</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP)</brief_title>
  <official_title>A SINGLE ARM, OPEN-LABEL, MULTI-CENTER, INTERVENTIONAL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEFTAZIDIME-AVIBACTAM (CAZ-AVI) IN CHINESE ADULTS WITH HAP (INCLUDING VAP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single arm, open-label, multi-center clinical study evaluating the&#xD;
      effectiveness and safety of CAZ-AVI in participants with HAP (including VAP), who have&#xD;
      initiated treatment with CAZ-AVI in an inpatient hospital setting. The duration of antibiotic&#xD;
      treatment with the CAZ-AVI is 7-14 days. Participants must receive intravenously (IV) CAZ-AVI&#xD;
      in the hospital for at least 7 full days. There are no formal hypothesis tests planned for&#xD;
      this study. The number and percent of participants having clinical cure, failure, and&#xD;
      indeterminate at TOC visit in the cMITT analysis population will be summarized.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2021</start_date>
  <completion_date type="Anticipated">February 13, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 13, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of HAP participants having clinical cure</measure>
    <time_frame>Test of Cure(TOC, Day 21 - 25)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of HAP participants having clinical cure</measure>
    <time_frame>Test of Cure(TOC, Day 21 - 25)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of HAP participants having clinical cure</measure>
    <time_frame>End of Treatment(EOT, participants were followed after the last IV dose but no later than 24 hours after the last IV dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of HAP participants having microbiological favorable response (per-patient and per-pathogen)</measure>
    <time_frame>Test of Cure(TOC, Day 21-Day 25)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of HAP participants with death</measure>
    <time_frame>Day 28 after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of HAP participants having clinical cure</measure>
    <time_frame>End of Treatment(EOT, participants were followed after the last IV dose but no later than 24 hours after the last IV dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of HAP participants having microbiological favorable response (per-patient and per-pathogen)</measure>
    <time_frame>Test of Cure(TOC, Day 21-Day 25)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of HAP participants having microbiological favorable response (per-patient and per-pathogen)</measure>
    <time_frame>End of Treatment(EOT, participants were followed after the last IV dose but no later than 24 hours after the last IV dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of HAP participants having microbiological favorable response (per-patient and per-pathogen)</measure>
    <time_frame>End of Treatment(EOT, participants were followed after the last IV dose but no later than 24 hours after the last IV dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of HAP participants with death</measure>
    <time_frame>Day 28 after enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">235</enrollment>
  <condition>Hospital-Acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>CAZ-AVI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zavicefta, Ceftazidime-Avibactam</intervention_name>
    <description>Participants will receive CAZ-AVI (2000 mg of ceftazidime and 500 mg of avibactam) administered by IV infusion in a volume of 100 mL at a constant rate over 2 hours.</description>
    <arm_group_label>CAZ-AVI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female participants ≥18 and ≤90 years of age.&#xD;
&#xD;
          -  Onset of symptoms ≥48 hours after admission or &lt;7 days after discharge from an&#xD;
             inpatient acute or chronic care facility.&#xD;
&#xD;
          -  New or worsening infiltrate on chest X-ray obtained within 48 hours prior to&#xD;
             screening.&#xD;
&#xD;
          -  Participants have systemic signs and respiratory signs or symptoms of HAP/VAP&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other medical or psychiatric condition may increase the risk of study participation&#xD;
             or, in the investigator's judgment, make the participant inappropriate for the study.&#xD;
&#xD;
          -  Participant is expected to require a treatment course for HAP longer than 14 days.&#xD;
&#xD;
          -  The total duration of antibiotic exposure for antibiotics whose administration begins&#xD;
             in the 48 hours is longer than 24 hours.&#xD;
&#xD;
          -  Previous administration with an investigational drug within 30 days or 5 half lives&#xD;
             preceding the first dose of study intervention used in this study (whichever is&#xD;
             longer).&#xD;
&#xD;
          -  Acute Physiology and Chronic Health Evaluation (APACHE) II score &gt;30 or &lt;10 using the&#xD;
             most recent available data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangzhou First People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Guangdong Medical University</name>
      <address>
        <city>Zhanjiang</city>
        <state>Guangdong</state>
        <zip>524000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NanYang First people's hospital</name>
      <address>
        <city>Nanyang</city>
        <state>Henan</state>
        <zip>47300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henan provincial people's hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430058</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hunan Provincial People's Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baotou Central Hospital</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia Autonomous Region</state>
        <zip>014000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jiangyin People's Hospital</name>
      <address>
        <city>Jiangyin</city>
        <state>Jiangsu</state>
        <zip>214400</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jiangyin People's Hospital</name>
      <address>
        <city>Jiangyin</city>
        <state>Jiangsu</state>
        <zip>214400</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial People's Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chengdu Xinhua Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610055</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Kunming</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhejiang Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhejiang Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The 2nd Affiliated Hospital of WMU</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325035</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wenzhou Central Hospital</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325099</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C3591026</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Healthcare-Associated Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftazidime</mesh_term>
    <mesh_term>Avibactam</mesh_term>
    <mesh_term>Avibactam, ceftazidime drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

